Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
15.83
-0.96 (-5.72%)
At close: Nov 15, 2024, 4:00 PM
16.00
+0.17 (1.07%)
After-hours: Nov 15, 2024, 7:59 PM EST
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for SNDX stock have an average target of 36, with a low estimate of 23 and a high estimate of 49. The average target predicts an increase of 127.42% from the current stock price of 15.83.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SNDX stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 7 | 7 | 7 | 7 | 8 |
| Buy | 3 | 2 | 3 | 3 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 10 | 11 | 11 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $47 → $49 | Strong Buy | Maintains | $47 → $49 | +209.54% | Nov 12, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $30 → $33 | Strong Buy | Maintains | $30 → $33 | +108.46% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $47 | Strong Buy | Maintains | $45 → $47 | +196.90% | Nov 6, 2024 |
| UBS | UBS | Strong Buy Initiates $37 | Strong Buy | Initiates | $37 | +133.73% | Oct 24, 2024 |
| Stifel | Stifel | Strong Buy Maintains $40 → $41 | Strong Buy | Maintains | $40 → $41 | +159.00% | Oct 14, 2024 |
Financial Forecast
Revenue This Year
35.46M
Revenue Next Year
113.43M
from 35.46M
Increased by 219.92%
EPS This Year
-3.77
from -2.98
EPS Next Year
-3.70
from -3.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 115.6M | 256.4M | 349.3M | ||
| Avg | 35.5M | 113.4M | 242.4M | ||
| Low | 2.0M | 58.9M | 176.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 623.3% | 208.0% | ||
| Avg | - | 219.9% | 113.7% | ||
| Low | - | 66.0% | 55.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.93 | -2.56 | -1.64 | ||
| Avg | -3.77 | -3.70 | -2.50 | ||
| Low | -4.07 | -4.82 | -3.17 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.